Italy’s Angelini Eyes Major Pharma Merger to Boost Drug Pipeline

Italian drugmaker Angelini Pharma SpA is looking at three US biotechs for a potential merger that would expand its global footprint and help it execute an ambitious growth plan.

Sergio Marullo di Condojanni, the chief executive officer of the drugmaker’s Rome-based holding company, Angelini Holding SpA, said in an interview that the ideal partner would have a pipeline of products in late clinical trials, and have released at least one drug to treat epilepsy, depression or schizophrenia. He declined to name any of the prospective counterparties.

“We’re currently reviewing a shortlist of about three biotech firms which are all ...